XML 28 R18.htm IDEA: XBRL DOCUMENT v3.3.0.814
SEGMENT REPORTING (Tables)
9 Months Ended
Sep. 30, 2015
Notes to Financial Statements  
Segment Reporting
     

 

Core

Companion

Animal Health

 

 

Other Vaccines,

Pharmaceuticals

and Products

 

 

 

 

Total

 

Nine Months Ended

September 30, 2014:

 
    Total revenue $ 51,223   $ 14,291     $ 65,514  
    Operating income (loss)   (545 )   1,702       1,157  
    Income before income taxes   (473 )   1,661       1,188  
    Total assets   82,294     14,790       97,084  
    Net assets   40,948     10,383       51,331  
    Capital expenditures   1,523     252       1,775  
    Depreciation and amortization   2,021     573       2,594  
       
 

Nine Months Ended

September 30, 2015:

 
    Total revenue $ 61,312   $ 13,526     $ 74,838  
    Operating income   2,768     2,224       4,992  
    Income before income taxes   2,703     2,184       4,887  
    Total assets   88,228     17,804       106,032  
    Net assets   46,696     12,463       59,159  
    Capital expenditures   677     1,299       1,976  
    Depreciation and amortization   2,712     528       3,240  
                             

 

     

 

Core

Companion

Animal Health

 

 

Other Vaccines,

Pharmaceuticals

and Products

 

 

 

 

Total

 

Three Months Ended

September 30, 2014:

 
    Total revenue $ 16,371   $ 5,434     $ 21,805  
    Operating income (loss)   (280 )   621       341  
    Income before income taxes   (227 )   608       381  
    Total assets   82,294     14,790       97,084  
    Net assets   40,948     10,383       51,331  
    Capital expenditures   189     48       237  
    Depreciation and amortization   790     187       977  
       
 

Three Months Ended

September 30, 2015:

 
    Total revenue $ 20,983   $ 7,051     $ 28,034  
    Operating income   697     1,445       2,142  
    Income before income taxes   782     1,429       2,211  
    Total assets   88,228     17,804       106,032  
    Net assets   46,696     12,463       59,159  
    Capital expenditures   228     812       1,040  
    Depreciation and amortization   988     178       1,166